Adial Pharmaceuticals

About:

Adial Pharmaceuticals develops prescription medications for addiction and related disorders.

Top Investors: Keystone Capital Partners, Bespoke Growth Partners, Richard Gilliam

Description:

Adial Pharmaceuticals engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed the Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed the Phase I clinical-stage for treating addictive behaviors.

Total Funding Amount:

$34.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Charlottesville, Virginia, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)adialpharma.com

Founders:

Bankole Johnson, William B. Stilley

Number of Employees:

11-50

Last Funding Date:

2024-03-02

IPO Status:

Public

Industries: